Skip to main content
. 2023 Jul 17;3(2):276–291. doi: 10.1016/j.gastha.2023.06.014

Table 3.

Summary of Current HBV Therapies

Types Notes
Interferon formulations
Conventional INF pegINF
  • -

    Poor efficacy and tolerability

  • -HBsAg loss after 5 y of follow-up occurs in <10% of patients91

  • -Should not be used in patient with decompensated liver failure92
TDF
Lamivudine
Telbivudine
Adefovir
ETV
TDF
TAF
Clevudine
Besifovir dipivoxila

  • -TAF is first-line treatment.

  • -TAF is more stable than TDF, thus able to more effectively deliver to hepatocytes.

  • -TAF has less renal and bone toxicity.11

  • -TAF is not recommended for CrCl <15 mL/min or those receiving dialysis.11

  • -ETV has no bone or renal toxicity risk.

  • -ETV is not recommended for women of childbearing age or for children.92

CrCl, creatinine clearance; NA, nucleos(t)ides analog.

a

Only available in Korea.